MA55404A - Compositions anticancéreuses - Google Patents

Compositions anticancéreuses

Info

Publication number: MA55404A
Authority: MA; Morocco
Prior art keywords: anticancer compositions; anticancer; compositions
Prior art date: 2014-12-05

Application number

MA055404A

Other languages

English (en)

French (fr)

Inventor

Geert Verreck

Original Assignee

Aragon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-05

Filing date

2015-12-03

Publication date

2022-02-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-03 Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc

2022-02-02 Publication of MA55404A publication Critical patent/MA55404A/fr

Links

230000001093 anti-cancer Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

MA055404A 2014-12-05 2015-12-03 Compositions anticancéreuses MA55404A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP14196591		2014-12-05

Publications (1)

Publication Number	Publication Date
MA55404A true MA55404A (fr)	2022-02-02

Family

ID=52006905

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA055404A MA55404A (fr)	2014-12-05	2015-12-03	Compositions anticancéreuses
MA41108A MA41108B1 (fr)	2014-12-05	2015-12-03	Compositions anticancéreuses

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA41108A MA41108B1 (fr)	2014-12-05	2015-12-03	Compositions anticancéreuses

Country Status (31)

Country	Link
US (3)	US20170360707A1 (2)
EP (2)	EP3842034B1 (2)
JP (1)	JP6767368B2 (2)
KR (1)	KR102348325B1 (2)
CN (2)	CN106999430A (2)
AR (1)	AR102924A1 (2)
AU (1)	AU2015358493B2 (2)
CA (1)	CA2969661C (2)
CL (1)	CL2017001372A1 (2)
CO (1)	CO2017005573A2 (2)
CR (1)	CR20170217A (2)
CY (1)	CY1123856T1 (2)
DK (1)	DK3226842T3 (2)
EA (1)	EA035988B1 (2)
ES (2)	ES2839128T3 (2)
HR (1)	HRP20201902T1 (2)
HU (1)	HUE051888T2 (2)
IL (1)	IL252324B (2)
LT (1)	LT3226842T (2)
MA (2)	MA55404A (2)
MD (1)	MD3226842T2 (2)
MX (1)	MX384382B (2)
NI (1)	NI201700069A (2)
PL (1)	PL3226842T3 (2)
PT (1)	PT3226842T (2)
RS (1)	RS61466B1 (2)
SG (1)	SG11201704264UA (2)
SI (1)	SI3226842T1 (2)
TW (1)	TWI683662B (2)
UA (1)	UA121123C2 (2)
WO (1)	WO2016090101A1 (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ744456A (en)	2012-09-26	2019-09-27	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG11201704267VA (en)	2014-12-05	2017-06-29	Aragon Pharmaceuticals Inc	Anticancer compositions
HUE054935T2 (hu)	2014-12-05	2021-10-28	Aragon Pharmaceuticals Inc	Rákellenes készítmények
US10702508B2 (en)	2017-10-16	2020-07-07	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
ES2967689T3 (es) *	2018-04-06	2024-05-03	Capsugel Belgium Nv	Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
WO2020144650A1 (en)	2019-01-10	2020-07-16	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of prostate cancer
KR20210122275A (ko)	2019-01-30	2021-10-08	얀센 파마슈티카 엔.브이.	분자 아형에 기초하여 전립선암을 치료하는 방법
EP3917519A1 (en)	2019-01-30	2021-12-08	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectedin for treating sarcomas based on genomic markers
US11723898B2 (en)	2019-11-04	2023-08-15	Aragon Pharmaceuticals, Inc.	Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en)	2020-06-05	2021-12-09	Janssen Pharmaceutica Nv	Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en)	2020-09-04	2022-03-10	Aragon Pharmaceuticals, Inc.	Methods for treating prostate cancer
WO2022195407A1 (en)	2021-03-19	2022-09-22	Aragon Pharmaceuticals, Inc.	Methods for treating prostate cancer
WO2023152611A1 (en)	2022-02-11	2023-08-17	Aragon Pharmaceuticals, Inc.	Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en)	2022-04-26	2023-11-02	Aragon Pharmaceuticals, Inc.	Approved drug products and methods for treating prostate cancer
CN121038790A (zh)	2023-03-16	2025-11-28	拜耳消费者护理股份有限公司	用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂
WO2026052846A1 (en)	2024-09-09	2026-03-12	Synthon B.V.	Pharmaceutical formulation comprising apalutamide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1381358B1 (en)	2001-04-02	2006-05-03	Astrazeneca AB	Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
WO2003077827A1 (en) *	2002-03-19	2003-09-25	Nippon Shinyaku Co., Ltd.	Process for producing drug solid dispersion
AU2003292509B2 (en) *	2003-12-15	2007-08-02	Council Of Scientific And Industrial Research	Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
SI2656842T1 (sl) *	2006-03-27	2016-10-28	The Regents Of The University Of California	Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
AU2011218173C1 (en) *	2010-02-16	2015-04-16	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
WO2012174436A1 (en) *	2011-06-15	2012-12-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2013152342A1 (en) *	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Anti-cancer mtor inhibitor and anti-androgen combination
EP2858985B1 (en)	2012-06-07	2018-04-18	Aragon Pharmaceuticals, Inc.	Crystalline forms of an androgen receptor modulator
US10668156B2 (en)	2012-06-22	2020-06-02	Basf Se	Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
JP6404217B2 (ja) *	2012-09-11	2018-10-10	メディベイションプロステイトセラピューティクスエルエルシー	エンザルタミドの製剤
NZ744456A (en) *	2012-09-26	2019-09-27	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2945628T3 (pl) *	2013-01-15	2020-09-21	Aragon Pharmaceuticals, Inc.	Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
WO2014114575A1 (en) *	2013-01-22	2014-07-31	F. Hoffmann-La Roche Ag	Pharmaceutical composition with improved bioavailability
WO2014167428A2 (en)	2013-04-10	2014-10-16	Shilpa Medicare Limited	Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CN105636594A (zh) *	2013-08-12	2016-06-01	托凯药业股份有限公司	使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
WO2015118015A1 (en) *	2014-02-05	2015-08-13	Lek Pharmaceuticals D.D.	Solid pharmaceutical compositions of androgen receptor antagonists

2015
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 EP EP20209559.2A patent/EP3842034B1/en active Active
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 CA CA2969661A patent/CA2969661C/en active Active
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/en active Active
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-03 CN CN202211487545.0A patent/CN115837010B/zh active Active
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro not_active IP Right Cessation
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh not_active IP Right Cessation
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/en not_active Ceased
- 2015-12-03 MX MX2017007201A patent/MX384382B/es unknown
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 HR HRP20201902TT patent/HRP20201902T1/hr unknown
- 2015-12-03 ES ES20209559T patent/ES3021508T3/es active Active
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active Active
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en not_active Abandoned
2024
- 2024-05-10 US US18/661,226 patent/US20240293321A1/en active Pending

Also Published As

Publication number	Publication date
AR102924A1 (es)	2017-04-05
AU2015358493B2 (en)	2021-05-06
TW201632187A (zh)	2016-09-16
PL3226842T3 (pl)	2021-07-12
US20220151931A1 (en)	2022-05-19
AU2015358493A1 (en)	2017-06-08
US20170360707A1 (en)	2017-12-21
CO2017005573A2 (es)	2017-09-29
MX384382B (es)	2025-03-14
EA035988B1 (ru)	2020-09-09
IL252324A0 (en)	2017-07-31
UA121123C2 (uk)	2020-04-10
MA41108A (fr)	2016-06-09
MA41108B1 (fr)	2021-03-31
CN115837010A (zh)	2023-03-24
CN106999430A (zh)	2017-08-01
ES2839128T3 (es)	2021-07-05
RS61466B1 (sr)	2021-03-31
CR20170217A (es)	2017-08-30
EP3226842B1 (en)	2020-11-25
CA2969661C (en)	2023-04-25
ES3021508T3 (en)	2025-05-27
CL2017001372A1 (es)	2018-01-05
TWI683662B (zh)	2020-02-01
BR112017011787A2 (pt)	2017-12-26
LT3226842T (lt)	2021-03-25
EP3226842A1 (en)	2017-10-11
JP6767368B2 (ja)	2020-10-14
CY1123856T1 (el)	2022-05-27
IL252324B (en)	2021-10-31
HRP20201902T1 (hr)	2021-07-23
JP2017536401A (ja)	2017-12-07
EP3842034B1 (en)	2025-02-12
SG11201704264UA (en)	2017-06-29
CA2969661A1 (en)	2016-06-09
CN115837010B (zh)	2025-03-14
KR20170086657A (ko)	2017-07-26
EA201791252A1 (ru)	2017-10-31
MD3226842T2 (ro)	2021-03-31
HUE051888T2 (hu)	2021-03-29
WO2016090101A1 (en)	2016-06-09
MX2017007201A (es)	2018-01-30
US20240293321A1 (en)	2024-09-05
PT3226842T (pt)	2020-12-23
KR102348325B1 (ko)	2022-01-06
EP3842034A1 (en)	2021-06-30
SI3226842T1 (sl)	2021-04-30
NI201700069A (es)	2017-10-31
DK3226842T3 (da)	2021-01-25

Publication	Publication Date	Title
IL279833A (en)	2021-01-31	Anti-cancer drugs
DK3151672T3 (da)	2021-02-01	Forbedrede t-celle-sammensætninger
DK3542812T3 (da)	2021-04-12	Glycopeptidsammensætninger
DK3226842T3 (da)	2021-01-25	Anticancersammensætninger
DK3089741T3 (da)	2021-06-07	Farmaceutiske sammensætninger omfattende azd9291
DK3040326T3 (da)	2020-03-30	Haloolefin-baseret sammensætning
DK3226843T3 (da)	2021-08-16	Anticancersammensætninger
FR3024363B1 (fr)	2018-08-10	Composition thermogelifiable
DK3250182T3 (da)	2023-06-26	Dispergible sammensætninger
DK3334726T3 (da)	2022-05-16	Plinabulinsammensætninger
DK3129007T3 (da)	2020-11-02	Vaccinesammensætninger
CL2017000639A1 (es)	2018-01-26	Composición
DK3316857T3 (da)	2021-10-18	Multifasiske sammensætninger
IL253276A0 (en)	2017-08-31	Anti-cancer compounds
HUE070090T2 (hu)	2025-05-28	Összetétel
DK3200827T3 (da)	2020-10-12	Sammensætninger
EP3298005C0 (en)	2024-01-24	ANTI-CANCER COMPOUNDS
DK3217964T3 (da)	2019-11-25	Sammensætning
FR3019552B1 (fr)	2016-04-01	Composition filmogene
DK3393503T3 (da)	2020-08-31	Sammensætninger